PENTIXAPHARM HLDG.
PTP.XETRA | Manufacture of pharmaceuticals, medicinal chemical and botanical products
PENTIXAPHARM HLDG, based in Germany, is a biopharmaceutical company focused on the development and commercialization of innovative radiopharmaceuticals for the diagnosis and treatment of various diseases, particularly in oncology. The company's activities include research and development, clinical t...Show More
Better Health for All
40
Pentixapharm's core business is dedicated to developing innovative radiopharmaceuticals for the diagnosis and treatment of severe diseases, including various cancers, cardiovascular, endocrine, and inflammatory conditions.
1
This focus on revolutionary health benefits for critical illnesses positions 100% of its portfolio as having a transformative global impact. The company has demonstrated an excellent safety record, with over 2,500 patients imaged with [68Ga]Ga-PentixaFor without any reported safety issues.
2
Pentixapharm actively invests in health innovation, developing novel radiopharmaceuticals and sponsoring more than 20 investigator-initiated clinical studies.
3
The company's clinical trial ethics are strong, with multiple ongoing Phase I/II and Phase III studies in Europe and the US, and positive FDA feedback on planned trials.
4
However, the company holds exclusive worldwide patent rights to its core CXCR4 technology, and while it has received Orphan Drug Designation for some products, there is no evidence of patent flexibility or voluntary licensing to improve global access, which is a negative factor for a pharmaceutical company.
5
Fair Money & Economic Opportunity
0
PENTIXAPHARM HLDG is a biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals. Its core business activities include research and development, clinical trials, manufacturing, and marketing of medical products. The company does not offer lending, insurance, deposit, or other financial services to consumers.
1
Therefore, all KPIs related to fair money and economic opportunity are not applicable to its operations.
Fair Pay & Worker Respect
0
No specific, concrete data points were found in the provided articles for any of the KPIs related to Fair Pay & Worker Respect for PTP.XETRA. The articles primarily focus on financial performance, strategic developments, and industry benchmarks for other companies, without providing direct evidence for PTP.XETRA's practices regarding living wage, CEO-median pay ratio, collective bargaining, safety incident rate, pay equity, worker engagement, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage. Information about Eckert & Ziegler (PTP.XETRA's former parent company) prior to the June 2024 spin-off is not directly applicable to PTP.XETRA's current performance.
1
Fair Trade & Ethical Sourcing
0
The provided articles contain no specific, concrete data points for any of the KPIs under the 'Fair Trade & Ethical Sourcing' value. All relevant articles explicitly state a lack of information regarding fair trade certifications, audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical sourcing clauses in supplier contracts, materials risk index, or supplier diversity spend.
1
Therefore, no KPIs can be scored based on the available evidence.
Honest & Fair Business
0
PTP.XETRA complies with the requirements of the Whistleblower Protection Act (HinSchG), but does not implement recommendations exceeding these requirements.
1
The company has not had any financial restatements in the past five years, with annual financial statements for 2024 audited by Mazars GmbH & Co. KG.
2
The company publishes various financial reports for years 2021-2025, including interim, half-year, and annual reports, as well as consolidated and individual financial statements.
3
Kind to Animals
-50
PENTIXAPHARM HLDG conducts preclinical development, which includes laboratory and animal studies, as part of the drug approval process.
1
However, the provided articles do not mention any explicit animal testing policy for the company.
2
No War, No Weapons
0
Pentixapharm Holding AG's core business is focused on radiopharmaceuticals for medical diagnosis and treatment, not arms or defense contracts.
1
Similarly, the company's R&D is exclusively focused on radiopharmaceuticals, indicating no development or sale of dual-use products.
2
No other information or specific data points related to arms manufacturing, military contracts, or conflict facilitation were found in the provided articles, leading to the omission of other KPIs.
Planet-Friendly Business
0
The provided articles, including the annual reports specifically for Pentixapharm Holding AG (PTP.XETRA), explicitly state a lack of information on environmental, social, and governance (ESG) metrics relevant to a planet-friendly business.
1
While some articles summarize sustainability reports from Eckert & Ziegler SE, they do not explicitly attribute the quantitative environmental data to PTP.XETRA.
2
Therefore, no specific, concrete data points for any of the Planet-Friendly Business KPIs could be found for PTP.XETRA.
Respect for Cultures & Communities
50
PENTIXAPHARM HLDG reports that 80.75% of its workforce is recruited from local communities, which exceeds the 70% threshold for the highest tier.
1
Safe & Smart Tech
0
No evidence available to assess PENTIXAPHARM HLDG on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No specific, concrete data points or verifiable facts were found in the provided articles regarding PTP.XETRA's waste diversion rate, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero-waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education programs. The company's 2024 annual report, as summarized in , explicitly states the absence of such quantitative data for these metrics.
1